Vaccine treatment for slow-growing lymphoma, alone or combined
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new vaccine medicine (EO2463) to treat indolent non-Hodgkin lymphoma (slow-growing lymphoma), either by itself or with other treatment. It may help your immune system recognize and attack lymphoma cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your lymphoma biopsy shows follicular lymphoma (FL) or marginal zone lymphoma (MZL), grade 1, 2, or 3A.
- Your body is able to do daily activities fairly well (ECOG 0 to 2, or 0 to 1 in some groups).
- You have measurable disease on scans, with a tumor/lymph node at least 1.5 cm in one measurement.
- You test positive for a specific immune marker called HLA-A2.
- You can attend all visits and give written consent before study procedures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (epcoritamab, zanubrutinib, and rituximab) for people with follicular lymphoma or marginal zone lymphoma that has come back after at least one prior treatment. The goal is to see if this new combination is safe and effective.
This phase 2 trial tests whether a combination of epcoritamab plus rituximab can work as a first treatment for follicular lymphoma. It may help people whose lymphoma is causing symptoms or affecting organs, or who have bulky disease, by targeting the lymphoma cells.
This trial tests a combination of two targeted drugs (rituximab and zanubrutinib) for people with slow-growing B-cell lymphomas like marginal zone or follicular lymphoma. It may be a good option if you haven't had treatment for your lymphoma before and your disease needs therapy to manage symptoms.
This trial tests a three-drug combination (pomalidomide, an anti-CD20 antibody, and prednisone) to treat certain slow-growing B-cell lymphomas that have never been treated before. The goal is to see if this combination works better than standard approaches.
This study tests combining the drug lenalidomide with a standard chemotherapy regimen (G-CHOP) for people newly diagnosed with a specific type of lymphoma that has both aggressive and slow-growing parts. The goal is to see if this combination works better than standard treatment alone.
This trial studies whether obinutuzumab combined with lenalidomide can control marginal zone lymphoma that has come back or not responded to prior treatment. If you qualify, you may receive these medicines together to help shrink tumors and improve symptoms.
Hear when a new Follicular Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.